2024-05-15T18:18:19-05:00 2023-06-30 581763570 JONES AND KOLB 3475 PIEDMONT ROAD NE SUITE 1500 ATLANTA GA 30305 990 2022-07-01 825476655 CMT Research Foundation Inc CMTR 4048067180 4062 Peachtree Road A209 Atlanta GA 30319 Erich Fasnacht COO 4048067180 2024-05-08 1 Erich Fasnacht 999009999 0 ANN M THOMPSON P00719770 4042627920 3 AAL1 IAL1 2022 2023-04-26 12:10:37Z Erich Fasnacht 4062 Peachtree Road A209 Atlanta GA 30319 3629014 0 X cmtrf.org X 2018 IL To fund research which delivers treatments and cures to end Charcot-Marie-Tooth (CMT). 12 10 6 25 0 0 4349158 3401534 0 48609 3127 76362 0 0 4352285 3526505 1051922 1835388 0 0 910443 946566 238367 134491 755209 398819 686211 2599551 3602656 1752734 -76151 3915699 4029470 75056 261301 3840643 3768169 With a single focus on funding research, the CMT Research Foundation exclusively funds research leading to the discovery, development, and clinical application of treatments and cures for Charcot-Marie-Tooth (CMT). 0 0 2493222 1835388 48609 Support the most promising and efficient Charcot-Marie-Tooth research aimed only toward drug delivery by developing strategic alliances with academic and industry stakeholders. 2493222 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 15 0 1 6 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 12 10 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 GA X The Organization 4048067180 4062 Peachtree Road Suite A209 Atlanta GA 30319 Patrick Livney Founder & Chairman 2.00 X X 0 0 0 Susan Ruediger Founder & Chief Mission Officer 40.00 X X 168941 0 33936 Susan Canavari Secretary 1.00 X X 0 0 0 Adam Kauffman Treasurer 1.00 X X 0 0 0 Cleary Simpson CEO 40.00 X X 191665 0 0 Paul August Member 2.00 X 0 0 0 Maximiliano Barrientos Member 1.00 X 0 0 0 Peter DeSilva Member 2.00 X 0 0 0 Joseph Mulvey Member 1.00 X 0 0 0 William Motley Member 2.00 X 0 0 0 Thomas Sander Member 1.00 X 0 0 0 Arthur Suckow Member 1.00 X 0 0 0 Erich Fasnacht Chief Operations Officer 40.00 X 230000 0 9975 Keith Fargo Chief Scientific Officer 40.00 X 200458 0 10345 791064 0 54256 4 0 1 0 0 199901 3201633 3401534 Convention Revenue 900099 48609 48609 48609 76362 76362 102509 199901 102509 0 3526505 48609 0 76362 1109673 1109673 725715 725715 698334 366858 61084 270392 179299 88219 17601 73479 18399 10594 1107 6698 50534 23338 7248 19948 69791 61869 7922 50542 5054 45488 134491 134491 69127 14258 44717 10152 18447 3820 14627 70792 3563 18169 49060 123966 46628 64676 12662 245377 13558 59297 172522 10934 10934 Miscellaneous 27235 20075 1355 5805 3602656 2493222 354225 755209 548993 466788 2854417 2130573 501704 1413262 10585 18847 3915699 4029470 72656 174134 2400 87167 75056 261301 X 379298 570361 3461345 3197808 3840643 3768169 3915699 4029470 -76151 3677 0 X 0 1 X 1 0 X 1526584 1686278 216898 4349158 3401534 11180452 1526584 1686278 216898 4349158 3401534 11180452 3726522 7453930 2969 1330 106 3127 76362 83894 86291 86291 11350637 0.65670 0.67330 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 3632691 3677 102509 106186 3526505 0 3526505 3705165 102509 102509 3602656 0 3602656 Part XI, Line 2d - Other Adjustments: Direct Cost of Special Events Part XII, Line 2d - Other Adjustments: Direct Cost of Special Events 1 0 0 0 0 0 0 0 0 0 Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgium Collaborative research agreement 366759 Wire Transfer 0 Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgium Collaborative research agreement 168570 Wire Transfer 0 Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgium Collaborative research agreement 37862 Wire Transfer 0 Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgium Collaborative research agreement 152524 Wire Transfer 0 0 0 0 0 0 0 Part III Accounting Method: Part I, Line 1: The Foundation executes collaborative research agreements with organizations that have expertise in the field of research, development and commercialization of therapeutic and diagnostic agents for human diseases and conditions. The Foundation ensures the grants and other assistance are used in accordance with the terms of the collaborative research agreements and produce results which help the Organization further its mission. X X 0 Allegiance Group 219 Roswell Street Alpharetta GA 30009 Digital Advertising 0 0 57600 0 Lotos Nile PO Box 90245 Nashville TN 37209 Marketing Services 0 0 30046 0 Ascenta Group Inc 138 South 1st St Ste 110 Lindenhurst NY 11757 Face to Face Marketing 0 0 46845 0 134491 Golf Tournament 302410 199901 102509 84984 302410 199901 102509 84984 84984 17525 1 University of Missouri 105 Jesse Hall Columbia MO 65211 100000 0 Collaborative research agreement University of Illinois at Chicago 1737 West Polk Street 304 AOB Chicago IL 60612 32385 0 Collaborative research agreement Edward Hines Jr VA Hospital 5000 South 5th Avenue Hines IL 60141 10000 0 Collaborative research agreement Vanderbilt University 2201 West End Avenue Nashville TN 37235 244323 0 Collaborative research agreement Nanite Inc 155 Arlington Street Watertown MA 02472 307965 0 Collaborative research agreement Samsara Therapeutics Inc 16192 Coastal Highway Lewes DE 19958 415000 0 Collaborative research agreement Part I, Line 2: The Foundation executes collaborative research agreements with organizations that have expertise in the field of research, development and commercialization of therapeutic and diagnostic agents for human diseases and conditions. The Foundation ensures the grants and other assistance are used in accordance with the terms of the collaborative research agreements and produce results which help the Organization further its mission. X 0 0 0 0 0 0 0 0 0 Susan Ruediger Founder & Chief Mission Officer 168941 0 0 0 0 0 5100 0 28836 0 202877 0 0 0 Cleary Simpson CEO 191665 0 0 0 0 0 0 0 0 0 191665 0 0 0 Erich Fasnacht Chief Operations Officer 230000 0 0 0 0 0 9750 0 225 0 239975 0 0 0 Keith Fargo Chief Scientific Officer 200458 0 0 0 0 0 9750 0 595 0 210803 0 0 0 Form 990, Part VI, Section B, line 11b The draft of the tax return is provided to the Organization's Board of Directors prior to filing. The comments received are addressed by management and the tax return preparer. Once the comments have been addressed, the tax return is signed by an officer of the Organization and filed. Form 990, Part VI, Section B, line 12c Annually, the Foundation requires officers, directors and key employees to affirm that no conflicts of interest exist. Potential conflicts are addressed on a case by case basis, consistent with the Foundation's written conflict of interest policy. Form 990, Part VI, Section B, line 15a The Foundation's independent Board of Directors determines the CEO's compensation. The CEO and COO determine the salaries of all other staff. Form 990, Part VI, Section C, line 19 The Organization makes its governing documents, conflict of interest policy and financial statements available to the public upon request.